Key Metrics
CiteScore 

0.7
H-Index 

32
Impact Factor 

< 5
SJR 

Q2Hematology

SNIP 

0.36
Recommended pre-submission checks
Powered by 

Topics Covered on Therapeutic Advances in Hematology
Therapeutic Advances in Hematology Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
DOAJ
SJR
| Overview | |
| Publisher | SAGE PUBLICATIONS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2300 |
| Publication Time | 7 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2010 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Therapeutic Advances in Hematology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Therapeutic Advances in Hematology
Clinical characteristics and outcome of CLL/SLL patients with renal involvement in the era of targeted drugs
- 1 Oct 2026
- Therapeutic Advances in Hematology
Low dose chidamide promotes inhibitory Fcγ receptorIIb expression on monocytes in ITP: A translational study of human ITP samples and ITP murine models
- 1 Oct 2026
- Therapeutic Advances in Hematology
Benefit of haploidentical hematopoietic stem cell transplantation for elderly patients with acute myeloid leukemia in first complete remission: A clinical observational study with in-depth time-dependent analysis
- 1 Oct 2026
- Therapeutic Advances in Hematology
Prognostic value of neutrophil-to-lymphocyte ratio among patients suffering from multiple myeloma: A systematic review and meta-analysis
- 1 Oct 2026
- Therapeutic Advances in Hematology
Emicizumab long-term outcomes and coagulation biomarkers in mild or moderate hemophilia A without inhibitors (HAVEN 6)
- 1 Oct 2026
- Therapeutic Advances in Hematology
Real-life venous thromboembolism risk scores in multiple myeloma receiving daratumumab, lenalidomide, and dexamethasone
- 1 Oct 2026
- Therapeutic Advances in Hematology
Clinical characteristics and outcome of CLL/SLL patients with renal involvement in the era of targeted drugs
- 1 Oct 2026
- Therapeutic Advances in Hematology
Low dose chidamide promotes inhibitory Fcγ receptorIIb expression on monocytes in ITP: A translational study of human ITP samples and ITP murine models
- 1 Oct 2026
- Therapeutic Advances in Hematology
Benefit of haploidentical hematopoietic stem cell transplantation for elderly patients with acute myeloid leukemia in first complete remission: A clinical observational study with in-depth time-dependent analysis
- 1 Oct 2026
- Therapeutic Advances in Hematology
Prognostic value of neutrophil-to-lymphocyte ratio among patients suffering from multiple myeloma: A systematic review and meta-analysis
- 1 Oct 2026
- Therapeutic Advances in Hematology
Emicizumab long-term outcomes and coagulation biomarkers in mild or moderate hemophilia A without inhibitors (HAVEN 6)
- 1 Oct 2026
- Therapeutic Advances in Hematology
Real-life venous thromboembolism risk scores in multiple myeloma receiving daratumumab, lenalidomide, and dexamethasone
- 1 Oct 2026
- Therapeutic Advances in Hematology